Catalyst Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Brian Elsbernd, Chief Legal Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Daniel J. Curran, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
David S Tierney, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Steve Miller, Chief Op. & Scientific Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Tamar Thompson, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Gregg Russo, Chief HR Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Patrick J Mcenany, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Donald A Denkhaus, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Carmen Jeffrey Del, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Richard J Daly, President and CEO and a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
William T. Andrews, Chief Medical Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Molly Harper, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Michael Wayne Kalb, Chief Financial Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.
NASDAQ
Chief Medical Officer William T. Andrews acquired 3,052 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.
NASDAQ
Catalyst Pharmaceuticals' Chief HR Officer, Gregg Russo, exercised restricted stock units and had shares withheld for taxes on February 17, 2026.
NASDAQ
Catalyst Pharmaceuticals' EVP & CFO, Michael Kalb, acquired shares from restricted stock unit vesting and disposed of a portion for tax obligations.
NASDAQ
Catalyst Pharmaceuticals CEO Richard J. Daly reported acquiring shares through a routine restricted stock unit vesting and subsequent tax-related sale.
NASDAQ
Catalyst Pharmaceuticals Director Donald A. Denkhaus converted 1,334 restricted stock units into common stock on December 29, 2025, increasing his direct common stock holdings.
NASDAQ
Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, reported the vesting of restricted stock units and subsequent tax-related share disposition.
NASDAQ
Catalyst Pharmaceuticals Director David S. Tierney acquired 1,334 shares of common stock following the vesting of restricted stock units.
NASDAQ
Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, increased her direct beneficial ownership of common stock following the vesting of restricted stock units.
NASDAQ
Catalyst Pharmaceuticals' Chief Operating & Scientific Officer, Steve Miller, acquired 14,000 shares of common stock following the vesting and delivery of restricted stock units.
NASDAQ
Catalyst Pharmaceuticals Director Molly Harper converted 1,334 restricted stock units into common stock on December 29, 2025, as part of a pre-planned vesting schedule.
NASDAQ
Patrick J. McEnany, Chairman of Catalyst Pharmaceuticals, reported the vesting of restricted stock units and subsequent tax-related share disposition.
NASDAQ
Catalyst Pharmaceuticals CEO Richard J. Daly reported the vesting and subsequent tax-related disposition of restricted stock units on December 29, 2025.
NASDAQ
Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the vesting of restricted stock units and subsequent sale of shares for tax withholding purposes.
NASDAQ
Catalyst Pharmaceuticals Director Molly Harper exercised stock options and subsequently sold a portion of the acquired shares for personal reasons, retaining 2,360 common shares.
NASDAQ
Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, acquired common stock through RSU vesting and simultaneously sold shares to cover tax obligations.
NASDAQ
Catalyst Pharmaceuticals' Chief Operating and Scientific Officer, Steve Miller, acquired 11,873 shares of common stock through the scheduled vesting of restricted stock units.